Med. Sci Res.,
1991 19, 827-828
Pharacokinetic studies of silybin-phosphatidylcholine
complex (Siliphos) in liver cirrhosis after multiple doses
Rocco Orlando, Annalisa Fragasso, Mario Lampertico1 and Carlo
Institute of Internal Medicine, University of Padua, Italy, and
1Medical Department, Inverni della Beffa, Milan, Italy
Journal not found on Medline
Introduction: Silybin is the main active component of silymarin,
a standardized extract from the seeds of Silybum marianum Gaertn.
(Siliphos) is a complex between silybin and soybean phosphatidylcholine,
which exerts protective effects against hepatic lesions induced
by toxic agents such as alcohol and phalloidin (1,2).
The data obtained in cirrhotic patients after multiple doses of
IdB 1016 (Siliphos) did not show significant differences from
those reported after a single dose. They clearly show that the
drug does not accumulate in cirrhotic patients.
Furthermore the results indicate no significant difference from
healthy control subjects.
It is therefore posited that this substance can be safely employed
in long-term treatment of chronic liver patients.
1. Ferenci, P., Dragosics, B., Frank, H. et al. 1985. Abstr. J.
Hepatol., 1, S229
2. Salmi, H.A. and Sarna, S. 1982, Scand. J. Gastroenterol., 17,